Inflammasome: development IL-1ß inhibitors
Opsona are developing compounds targetting the Inflammasome, strategically complementing our pipeline of innate immune modulators.
Pathologies such as gouty arthritis, Muckle-Wells syndrome or CINCA have been shown to be dependent on Inflammasome activity. In vitro and in vivo experiments have been carried out to validate this as a target for an innovative drug development programme.
Early development studies confirmed drugability of the inflammasome and its tremendous potential as a specific IL1-ß inhibitor.
Opsona is active in a small molecule Inflammasome modulator programme.